MANKIND - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | MANKIND | Market Cap | 86,849 Cr. | Current Price | 2,103 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 49.2 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,155 ₹ | DMA 200 | 2,285 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 513 Cr. | PAT Prev Qtr | 459 Cr. |
| RSI | 45.4 | MACD | 0.42 | Volume | 3,23,555 | Avg Vol 1Wk | 4,66,297 |
| Low price | 2,012 ₹ | High price | 2,727 ₹ | PEG Ratio | 5.84 | Debt to equity | 0.47 |
| 52w Index | 12.7 % | Qtr Profit Var | 24.5 % | EPS | 41.3 ₹ | Industry PE | 27.6 |
📊 Analysis: Mankind Pharma shows moderate momentum for intraday trading today. RSI at 45.4 indicates neutral conditions, while MACD is slightly positive (0.42), suggesting mild bullishness. Current price (2,103 ₹) is below both 50 DMA (2,155 ₹) and 200 DMA (2,285 ₹), showing short-term and medium-term weakness. Volume is lower than the 1-week average, indicating reduced participation, which limits strong intraday conviction.
💡 Optimal Buy Price: Around 2,095–2,110 ₹ if intraday support holds.
🎯 Profit Exit Levels: 2,135 ₹ (first target), 2,160 ₹ (second target if momentum improves).
⚠️ Stop-Loss: 2,080 ₹ to protect against downside risk.
📌 If Already Holding: Consider exiting near 2,135–2,160 ₹ if momentum indicators remain flat. If price falls below 2,080 ₹ with volume confirmation, exit to avoid deeper losses.
✅ Positive
- Quarterly PAT growth (513 Cr. vs 459 Cr.).
- EPS at 41.3 ₹ supports earnings visibility.
- ROCE (15.0%) and ROE (13.9%) indicate decent capital efficiency.
- DII holdings increased (+1.35%), showing strong domestic support.
⚠️ Limitation
- Price trading below both 50 DMA and 200 DMA, showing weakness.
- PEG ratio at 5.84 indicates overvaluation relative to growth.
- Dividend yield at 0.05% is very low, limiting income appeal.
- Volume below average, limiting intraday participation.
📉 Company Negative News
- FII holdings decreased (-1.49%), showing reduced foreign confidence.
- 52-week index at 12.7% shows severe underperformance relative to highs.
📈 Company Positive News
- Quarterly profit growth of 24.5% shows operational improvement.
- DII holdings increased significantly (+1.35%), showing domestic investor confidence.
🏭 Industry
- Pharma sector trading at PE ~27.6, Mankind Pharma is overvalued with P/E of 49.2.
- Sector demand remains defensive, benefiting from healthcare expansion and exports.
🔎 Conclusion
Mankind Pharma is a fair intraday candidate today with mild bullish signals but weak technicals. A cautious buy near 2,095–2,110 ₹ with targets at 2,135 ₹ and 2,160 ₹ offers limited opportunity, but traders should maintain a strict stop-loss at 2,080 ₹. Better suited for swing trades if price sustains above 2,155 ₹ (50 DMA) with improving momentum.
Would you like me to prepare a peer benchmarking overlay with other pharma majors (like Sun Pharma, Cipla, Dr. Reddy’s) so you can compare Mankind Pharma’s intraday strength against sector leaders?